California's $8.4 Billion Immunology Research Bond Heads to Voters Amid Federal Funding Crisis
核心洞察
Proposition 38 would authorize $8.4 billion in state bonds for immunology and immunotherapy research, with half earmarked for cancer, heart disease, and Alzheimer's disease.
The measure would equally fund a UC-affiliated nonprofit research institute and a grant program for California public or nonprofit universities and institutions.
Supporters argue the bond is critical to offset NIH funding cuts that have disrupted clinical trials, with UC alone losing over $37 million in canceled federal grants.
California voters will decide this November whether to authorize $8.4 billion in state general obligation bonds to fund immunology and immunotherapy research, a ballot measure that supporters say could rescue medical science from sweeping federal funding cuts while critics warn it commits the state to decades of debt for a narrow slice of research.
The proposed California Immunology Research and Cures Initiative, designated Proposition 38, would allocate funding equally between a University of California-affiliated nonprofit medical research institute — to be selected by the California Department of Public Health — and a grant program open to public or nonprofit universities and institutions across the state. Half of all research funding must be directed toward cancer, heart disease, and Alzheimer's disease, with the remaining half available for discretionary use on other diseases and illnesses.
A Response to Federal Retreat
The measure arrives at a moment of acute distress for biomedical research. Over the past year, the Trump administration froze or cut at least $2.3 billion in previously approved and unspent NIH grants, canceling hundreds of research projects. The impact has been particularly severe in the Bay Area, where universities and medical centers have lost more than $55 million in canceled federal grants. The University of California system alone estimated losses exceeding $37 million, while California State University reported at least $7 million in cuts.
"Several of our patients had to stop their treatment in a clinical trial because the funding was gone," said Adam Zarrin, director of state government affairs at Blood Cancer United (搜索). "The same is happening for the researchers: 'We're in the middle of a trial, we're in the middle of doing our work and now the federal government has taken action and we no longer have access to the resources that we need to continue this research.'"
Shane Crotty, chief science officer at the La Jolla Institute for Immunology, described the toll on the scientific workforce. "It feels like you've got a team of people rolling a boulder up a hill. So if you have a pause in the resources, some of those people are leaving, the boulder definitely starts going back down the hill," he said. "I think that's what it feels like for a lot of people doing medical research right now."
The Human Stakes
The transformative potential of immunotherapy is exemplified by patient stories like that of Laurie Adami, who was diagnosed in 2006 at age 46 with late-stage follicular non-Hodgkin lymphoma (搜索). By 2018, doctors estimated she had over eight pounds of cancerous tumors and less than a month to live. Her seventh and final treatment — Chimeric Antigen Receptor T-cell therapy, or CAR-T (搜索) — genetically reprogrammed her white blood cells to hunt and destroy cancer cells. Within 30 days, she was cancer-free.
"That shows the power of this new treatment, which is like nothing else has ever been," Adami said. "And if I hadn't done CAR-T (搜索) when I got it, I would've been dead within a month."
Adami had known about CAR-T (搜索) since 2012 but was forced to wait six years due to research delays and a lack of clinical trials for her cancer type. She now works as a patient advocate and recounted the human cost of recent funding disruptions: "There was a family I knew who had a young child with leukemia who had failed everything and was in a clinical trial that got shut down because of the NIH cuts last year, and the child died."
Financial Structure and Safeguards
The bonds would be repaid through the state's general fund, with estimated costs of approximately $500 million annually over 25 years, according to the state's Legislative Analyst's Office. Some of that expenditure could be recouped if funded research leads to revenue-generating discoveries.
The measure includes several built-in financial provisions. It would cap state administrative costs at 2%, mandate that 10% of all licensing revenues from developed treatments be returned to California to offset bond costs, and require that any technology or drugs derived from the research be sold in California at 20% below the national average price. No funds would be awarded to for-profit organizations or pharmaceutical companies.
Support and Opposition
The bond is backed by dozens of disease advocacy groups, including Blood Cancer United (搜索), the ALS Association, the Alzheimer's Association, and the Parkinson Association of Northern California. It is primarily funded and promoted by billionaire philanthropist and medical inventor Dr. Gary K. Michelson, who pledged $120 million in 2024 to launch the California Institute for Immunology and Immunotherapy (搜索), a UCLA-affiliated research center expected to open in 2027.
Opposition has centered on the narrow scope of the funding and the long-term debt commitment. Robert M. Kaplan, an adjunct professor at the Stanford School of Medicine Clinical Excellence Research Center, wrote in an opinion piece for the Sacramento Bee that "this approach risks turning research funding into a series of competing campaigns, leaving less visible but equally important conditions behind."
State Sen. Scott Wiener, who had proposed a broader $23 billion scientific research bond that failed to make the November ballot, also criticized the measure as too narrow.
Crotty countered that the investment could yield rapid returns for patients. "This type of investment in immune system medical research could really mean better health and better therapies for patients and can do so pretty quickly," he said. "The federal situation has created a bottleneck for advances that are on the cusp from really moving forward."
Adami framed the measure as both a scientific and moral imperative: "This $8.4 billion is going to give us this huge leg up and get research kick-started where it should be and across all of our California research institutions and medical research facilities. And why shouldn't California lead immunotherapy research?"